Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 12, Issue 10, 2010, Pages 923-925

  Swinnen, S G ^a   Dain, M P ^b   Mauricio, D ^c   DeVries, J H ^a   Hoekstra, J B ^a   Holleman, F ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b SANOFI   (France)

^c HOSPITAL ARNAU DE VILANOVA   (Spain)

Author keywords

Antidiabetic drug; Clinical trial; Insulin secretagogue; Insulin therapy; Type 2 diabetes

Indexed keywords

GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN DETEMIR; INSULIN GLARGINE; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETIC PATIENT; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; SIDE EFFECT; TREATMENT WITHDRAWAL; WEIGHT GAIN;

EID: 77956149675     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01258.x     Document Type: Article

References (6)

1. Nathan DM, Buse JB, Davidson MB. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203..
2. Raskin P. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes. Diabetes Metab Res Rev 2008, 24:3-13..
3. Riddle MC. Combined therapy with insulin plus oral agents: is there any advantage? Diabetes Care 2008, 31:S125-S130..
4. Swinnen SG, Snoek FJ, Dain MP, DeVries JH, Hoekstra JB, Holleman F. Rationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study: a multinational, randomized non-inferiority trial of basal insulin initiation in type 2 diabetes. Diabetes Technol Ther 2009, 11:739-743..
5. Vickers AJ, Altman DG. Statistics notes: analysing controlled trials with baseline and follow up measurements. BMJ 2001, 323:1123-1124..
6. Roden M. Optimal insulin treatment in type 2 diabetes. N Engl J Med 2009, 361:1801-1803..